[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biomarkers--hair\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biomarkers--hair":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100600111","epigenetic-optimization-through-biofrequency-nutrition-100600111",false,"NCT07093242","Epigenetic Optimization Through Biofrequency Nutrition","Functional Epigenetic Optimization Through Biofrequency-Guided Nutrition: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 65 years.\n* Active member of a registered athletics club.\n* Willingness to provide a hair sample for genetic analysis.\n* Ability to understand and sign the informed consent form.\n* Commitment to complete the nutritional follow-up (for the intervention group) and to respond to pre- and post-intervention questionnaires.\n\nExclusion Criteria:\n\n* Prior medical diagnosis of a genetic disorder affecting nutritional metabolism.\n* Current use of nutritional supplements or special diets prescribed for medical reasons.\n* Participation in another clinical or nutritional study during the intervention period.\n* Pregnancy or breastfeeding at the time of enrollment.\n* Inability to attend baseline or post-intervention assessments.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","Biomarker-based nutrition has demonstrated superior efficacy compared to population-level approaches in improving health outcomes. Biofrequency analysis, a non-invasive technique based on the detection of electromagnetic vibrational patterns in hair follicles, offers a promising avenue for rapid functional assessment of nutritional status and epigenetic signals without reliance on blood or urine sampling. First, to evaluate the effect of a 90-day biofrequency-guided nutritional intervention on functional epigenetic status, as reflected in changes in the optimization report generated by the S-Drive system; second, to assess changes in adherence to the Mediterranean diet, anthropometric indicators, movement behaviors, and psychological well-being. Methods: In this randomized controlled trial, adults from a Sport Team from Region of Murcia (Spain) will be allocated to an experimental group receiving individualized lifestyle recommendations based on S-Drive biofrequency analysis and to a control group with no intervention. Participants in the experimental arm will apply tailored dietary guidance over 90 days. Conclusion: This study will generate foundational evidence on the utility of biofrequency technology for precision nutrition. If positive, the findings may inform scalable, low-risk strategies for personalized dietary interventions in preventive and community health settings.",[28,29,30],"Nutrition Habits","Biomarkers \u002F Hair","Epigenetic",[32,33,34,35,36],"Biofrequency analysis","young athletes","nutritional intervention","nutritional biomarkers","mediterranean diet","NOT_YET_RECRUITING","2025-07-22",{"date":40,"type":41},"2025-07-30","ACTUAL",{"date":43,"type":22},"2025-10-01",{"date":45,"type":22},"2026-02-01",{"name":47,"class":48},"Universidad de Almeria","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100564990","phase-2-nitrous-oxide-in-the-treatment-of-acute-suicidal-ideation-100564990","NCT06636357","Nitrous Oxide in the Treatment of Acute Suicidal Ideation","NITOS","Inclusion criteria:\n\n* Ability to give written informed consent\n* Moderate to severe suicidal ideation defined as a score ≥3 on the Montgomery-Asberg Depression Rating Scale (MADRS; Schmidtke et al., 1985) suicide item (item #10) as well as a self-report Beck Scale for Suicide Ideation (BSS; Kliem et al., 2017) items #4 plus #5 score ≥ 2\n* Plasma homocysteine level ≤ 14 µmol\u002Fl\n\nExclusion criteria:\n\n* Organic, including symptomatic, mental disorders (F00-F09; lifetime diagnosis)\n* Schizophrenia, schizotypal and delusional disorders (F20-F29; lifetime diagnosis)\n* Mental and behavioral disorders due to psychoactive substance use. Nicotine and cannabis will be ignored (F10-F19)\n* Non-medical (i.e., recreational) use of inhalational N2O during the last 12 months\n* Past intolerance or hypersensitivity to N2O\n* Critical illness\n* Severe cardiac disease\n* Pregnancy or breastfeeding\n* Pulmonary hypertension\n* Chronic cobalamin or folate deficiency unless treated with folic acid and\u002For vitamin B12\n* History or evidence of any other medical or neurological condition that would expose the subject to an undue risk of a significant adverse event as determined by the clinical judgment of the investigator\n* Treatment with ketamine\u002Fesketamine during the last 4 weeks\n* Treatment with opioid medications during the last 3 months\n* Treatment with vagus nerve stimulation (VNS) or electroconvulsive therapy (ECT) within the last 3 months\n* Recent (within the last 4 weeks) or current use of benzodiazepines in excess of 5 mg lorazepam or equivalent per day\n* Finally, any other factors that, in the investigator's judgment, would unduly impact patient safety or compliance during the study.",{"count":57,"type":22},85,[59],"PHASE2","The primary aim of the NITOS study is to investigate the potential rapid antisuicidal effects of N2O in the transdiagnostic treatment of suicidal ideation. On day 1, patients will receive either nitrous oxide (50% N2O balanced with oxygen) or placebo (50% oxygen balanced with air). Seven days after the first inhalation, a second inhalation will be performed. All patients will receive N2O at least once during this trial. While the first inhalation will be double-blind, only the patients but not the raters will be blinded to the second inhalation (day 8). For mechanism of action and prediction, a nested biomarker substudy will employ multimodal techniques including analysis of hair and blood samples, and EEG.",[62,63,64,65,66,29],"Suicidality","EEG","Suicidal Ideation","Nitrous Oxide","Biomarkers \u002F Blood",[68,69,70,71],"suicidality","nitrous oxide","suicidal ideation","depression","RECRUITING","2025-01-13",{"date":75,"type":41},"2025-01-16",{"date":73,"type":41},{"date":78,"type":22},"2026-09-30",{"name":80,"class":48},"University of Zurich",1]